1. Beal MF, Richardson EP Jr, Martin J. Alzheimer's Disease and Other Dementias. In [eds: Isselbacher AB, Braunwald E, Wilson JD, et al] Harrison's Principles of Internal Medicine. 1994;1:2269-2272.

2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. For the REVARSAL Investigators. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: a Randomized Controlled Trial. JAMA. 2004;291:1071-1080.

3. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of Aggressive Versus Conventional Lipid Lowering on Atherosclerosis Progression in Familial Hypercholerserolemia (ASAP): a Prospective, Randomized, Double-Blind Trial. Lancet. 2001;357:577-581.

4. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a Randomizied Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness. Circulation. 2002;106:2055-2060.

5.Feron o, Bellhausen L, Kobzik L, et al. Endothelial Nitric Oxide Synthase Targeting to Caveolae:Sprecific Interactions With Caveolin Isoforms in Cardiac Myocytes and Endothelial Cells. J Biol Chem. 1996;271:22810-22814.

6. Michel T, Feron O. Nitric Oxide Synthases: Which, Where, How, and Why? J Clin Invest. 1997;100:2146-2152.

7. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia Decreases Nitric Oxide Production by Promoting the Interaction of Caveolin and Endothelial Nitric Oxide Synthase. J Clin Invest. 1999;103:897-905

8. Rosario ER Chang L, Stancyzk FZ, et al. Age-Related Testosterone Depletion and the Development of Alzheimer Disease. JAMA. 2004;292:1431-1432.

9. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-Co A Reductase Inhibition by Atorvastatin Reduced Neointimal Inflammation in a Rabbit Model of Atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.

10. Jen s, Wall U, Bergbrant A, et al. Endothelium-Dependent Vasodilation and Tissue-Type Plasminogen Activator Release in Borderline Hypertension. Arterio Scler Throm Vasc Biolo. 1997;17:3376-3388.

11.van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris. Circulation. 1996;94:1503-1505.

12. Libby P. Molecular Basis of the Acute Coronary Syndromes. Circulation. 1995;91:2844-2850.

13. Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation. 1995;104:365-372.

14. Aikawa M, Rabkin E Okada Y, et al. Lipid Lowering By Diet Reduces Matrix Metalloproteinace Activity and Increases Collagen Content of Rabbit Atheroma: A Potential Mechanism of Lesion Stabilization. Circulation. 1998;97:2433-2444.

15. Boucier T, Libby P. HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells. Atheroscler Thromb Vasc Biol. 2000;20:556-562.

16.www.familydoctor.org Memory Loss With Aging: What=s Normal, What=s Not. http://familydoctor.org/124.xml? 1/14/06.

17.Mild Cognitive Impairment. http://www.mayoclinic.com/health/mild-cognitive-impairment/DS00533 1/14/06.

18. Klatzo, I., Wisniewski, H.M., Streicher, E. Experimental Production of Neurofibrillary Degeneration. J. Neuropath. & Exp. Neurol., 1965, 24: 187-199.

19. Wisniewski, H.M., Terry, R.D., Peña, C., Streicher, E., Klatzo, I. Experimental Production of Neurofibrillary Degeneration. J. Neuropath. & Exp. Neurol., 1965, 24: 139.

20. Terry, R.D., Peña, C. Experimental Production of Neurofibrillary Degeneration. J. Neuropath. & Exp. Neurol., 1965, 24: 200-210.

21. Wisniewski, H.M., Wen, G.Y. Aluminum and Alzheimer=s Disease. Aluminum in Biology and Medicine. Wiley, Chichester (Ciba Foundation Symposium 169), 1992, pp. 142-164.

22. Savory, J., Huang, Y., Herman, M.M. Reyes, M.R., Wills, M.R. Tau Immunoreactivity Associated with Aluminum Maltolate-induced Neurofibrillary Degeneration in Rabbits. Brain Res., 1995, 669: 325-329.

23. Singer, S.M., Chambers, C.B., Newfry, G.A., Norlund, M.A., Muma, N.A. Tau in Aluminum-Induced Neurofibrillary Tangles. NeuroToxicology, 1997, 18: 63-76

24. McLachlan, D.R.C., Dalton, A.J., Kruck, T.P.A., Bell, M.Y., Smith, L.W., Kalow, W., Andrews, D.F. Intramuscular Desferrioxamine in Patients with Alzheimer=s Disease. Lancet, 1991, 337: 1304-1308.

25. McLachlan, D.R.C., Smith, L.W., Kruck, T.P. Desferrioxamine and Alzheimer=s Disease: Video Home Behavior Assessment of Clinical Course and Measures of Brain Aluminum. Therapeutic Drug Monitoring. 1993, 15: 602-607.

26. Dementia. Malehealth. http://www.malehealth.co.uk/userpage1.cfm?item_id=119. 1/25/06.

27. Alzheimer=s Disease. Numark Pharmacists.

28. The Franklin Institute Online. The Human Brain: Protect: Heavy Metals. http://www.fi.edu/brain/metals.htm. 1/25/06.

29 MercuryPoisoned.com. Alternative Treatments For Neurological Disease. http://www.mercurypoisoned.com/new/alternative.html. 1/25/06

30. Sturgeon B. Mercury and Alzheimer=s Disease. Senior News. 2003;22(2). http://www.humguide.com/seniornews/issues/0302d.shtml. 1/25/06

31. Kingman A, Albers JW, Arezzo JC, Garabrant DH, Michalek JE. Amalgam exposure and neurological function. Neurotoxicology. 2005 Mar;26(2):241-55.

32. Yaffe, K, Kanaya A, Lindquist K, eta al. The Metabolic Syndrome, Inflammation and Risk of Cognitive Decline. JAMA. 2004;292:2237-2242.

33. Finot PA. Historical Perspective of the Maillard Reaction in Food Science. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:1-8.

34. Rahbar S. The Discovery of Glycated Hemoglobin: A Major Event in the Study of Non-enzymatic Chemistry in Biological Systems. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:9-19.

35. Uribarri J, Cai W, Sandu O, et al. Diet-Derived Advanced Glycosylation End Products Are Major Contributors to the Body=s AGE Pool and Induce Inflammation in Healthy Subjects. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:452-460.

36. Monnier VM, Mustata GT, Biemel KL, et al. Cross-Linking of the Extracellular Matrix by the Maillard Reaction in Aging and Diabetes. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:533-544.

37. Moriera PI, Smith MA, ZHU X, et al. Oxidative Stress and Neurodegeneration. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:545-552.

38. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-Co A Reductase Inhibition by Atorvastatin Reduced Neointimal Inflammation in a Rabbit Model of Atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.

39. Jen S, Wall U, Bergbrant A, et al. Endothelium-Dependent Vasodilation and Tissue-Type Plasminogen Activator Release in Borderline Hypertension. Arterio Scler Throm Vasc Biolo. 1997;17:3376-3388.

40. De Caterina R, Libby P, Peng HB. Nitric Oxide Decreases Cytokine-Induced Endothelial Activation: Nitric Oxide Selectivity Reduces Endothelial Endothelial Expression of Adhesion Molecular and Proinflammatory Cytokines. J Clin Invest. 1995;66:60-68.

41. Knopman DS. Dementia and Cerebrovascular Disease. Mayo Clin Proc. 2006;81(2):223-230

42. Thomas MC, Forbes JM, MacIssac R, et al. Low-Molecular Weight Advanced Glycation End Products: Markers of Tissue AGE Accumulation and More? In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:644-654.

43 Bierhaus A, Humpert PM, Stern DM, et al. Advanced Glycation End Product Receptor-Mediated Cellular Dysfunction. In The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease. Baynes JE, Monnier VM, Ames JM, Thorpe SR Eds. Annals of New York Acad Sciences. 2005;1043:676-680.

44. Burkhardt MS, Foster JK, Laws SM, et.al. Oestrogen Replacement Therapy may Improve Memory Functioning in the Absence of APOE epsilon4. J Alzheimers Dis 2004;6(3):229-230.

45. Erickson KI, Colcombe SJ, Raz N, et.al. Selective Sparing of Brain Tissue in Postmenopausal Women Receiving Hormaone Replacement Therapy. Neurobiol Aging. 2005;26(8):1205-1213.

46. Racchi M, Govoni S, Solerte, et.al. Dehydroepiandroserone and the Relationship With Aging and Memory: A Possible Link With Protein Kinase C Functional Machinery. Brain Res Rev. 2001;37(1-3):287-293.

47. Valee M, Shen W, Heinrichs SC, et. Al. Steroid Structure and Pharmacological Properties Determine the Anti-Amnesic Effects of Pregnenolone Sulphate in Passive Avoidance Task in Rats. Eur J Neurosci. 2001;14(12):2003-2010.

48. Thornton PL, Ingram RL, Sonntag WE. J Gerontol A Biol Sci Med Sci. 2000;55(2):B106-112.

49. Sonntag WE, Lynch C. Thornton P, et. al. The Effects of Growth Hormone and IGF-1 Deficiency on Cerebrovascular and Brain Ageing. J Anat. 2000;197(Pt4):575-585.

50. Nelson RB. The Dualistic Nature of Immune Modulation in Alzheimer=s Disease: Lessons from the Transgenic Models. Curr Pharm Des. 2005;11(26)3335-3352.

51. Streit WJ, Condi JR, Fenwick, SE, at.al. Role of Microglia in the Central Nervous System=s Immune Response. Neurol Res. 2005;Oct27(7):685-691.

52. Huang y, Erdmann N, Peng H, Zhao Y, Zheng J. The Role of TNF related apoptosis-inducing Ligand in Neurodegenerative Diseases. Cell Mol Immunol. 2005 April;2(2):113-122.

53. Borson S, Scanlan J, Brush M, et.al. The Mini-Cog: A Cognitive Vital Signs= Measure for Dementia Screening in Multi-Lingual Elderly. Int J Geriatr Psychiatry. 2000;15:1021-1027.

54. Borson S, Scanlan J, Chen P, et.al. The Mini-Cog as a Screen for Dementia: Validation in a Population-Based Sample. J Am Geriatr Soc. 2003;51:1451-1454.

55. Borson S, Brush M, Gil E, et.al. The Clock Drawing Test:Utility for Dementia Detection in Multiethnic Elders. J Gerontol A Biol Sci Med Sci. 1999;54:M534-M540.

56. Borson S, Scanlan JM, Watanabe J, et.al. Simplifying Detection of Cognitive Impairment: Comparison of the Mini-Cog and Mini-Mental State Examination in a Multiethenic Sample. J Am Geriatr Soc. 2005;53:871-874.

57. Shankle WR, Romney AK, Hara J, et.al. Methods to Improve the Detection of Mild Cognitive Impairment. Proc Natl Acad Sci U S A. 2005;102:4919-4924.

58. Buschke H, Kuslusky G, Katz M, et.al. Screening for Dementia With the Memory Impairment Scree. Neurology. 1999;52:231-238.

59. Brodaty H, Pond D, Kemp NM, et.al. The GOCOG: A New Screening Test for Dementia Designed for General Practice. J Am Geriatr Soc. 2002;50:530-534.

60. Larson EB, Wang L, Bowen JD, et. al. Exercise is Associated With Reduced Risk for Incident Dementia Among Persons 65 Years of Age and Older. Ann Int Med. 2006;144:73-81.

61. Lai MW, Moen M. Pesticide-Like Poisoning From a Prescription Drug. N Engl J Med. 2005;353(3):317.

62. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt T, van der Bussche H. Cholinesterase Inhibitors for Patients With Alzheimer=s Disease: A Systematic Review of Randomized Clinical Trials. British Medical J. 2005;331:321-327.

63. Luckman R. Review: Cholinesterase Inhibitors May Be Effective in Alzheimer Disease. ACP Journal Club. 2006;144(1):19.

64. Zoler ML, Wendlin P. Drug Update: Alzheimer=s Disease. Internal Medicine News. July 1, 2005:44

65. Otsuka M, Yamaguchi K, Ueki A. Similarities and Differences Between Alzheimer=s Disease and Vascular Dementia From the Viewpoint of Nutrition. Ann N Y Acad Sci. 2002 Nov;977:155-161.

66. Finn R. Insulin Sensitizers Cut Cognitive Decline in AD. Internal Medicine News. 2006;39 (2):44.

67. Lin AMY, Chen KB, Chao PL, Antioxidative Effect of Vitamin D3 on Zinc-Induced Oxidative Stress in CNS. In Neuroprotective Agents: Seventh International Conference. Slikker, W, Andrews RJ, Trembly B Eds. New York Acad Sci. 2005;1053:310-329.

68. Tam D, Tam M, Maynard KI.. Nicotinamide Modulates Energy Utilization and Improves Functional Recovery From Ischemia in the In Vitro Rabbit Retina. In Neuroprotective Agents: Seventh International Conference. Slikker, W, Andrews RJ, Trembly B Eds. New York Acad Sci. 2005;1053:258-268.

69. Perianayagam MC, Oxenkrug GF, Jaber BL. Immune-Modulating Effects of Melatonin. In Neuroprotective Agents: Seventh International Conference. Slikker, W, Andrews RJ, Trembly B Eds. New York Acad Sci. 2005;1053:310-329.

70. Roach ES, McLean WT. Neurologic Disorders of Vitamin b12 Deficiency. Am Fam Physic. 1982 Jan;(1):111-115.

71. Clark R, Smith AD, Jobst KA, et. al. Folate, Vitamin B12 and Serum Homocysteine Levels in Confirmed Alzheimer Disease. Arch Neurol. 1998 Nov;55(11):1449-1445.

72. Hassing L, Wahlin A, Winblat B, Backman L. Further Evidence on the Effects of Vitamin B12 and Folate Levels on Episodic Memory Function: A Population-based Study of Healthy Very Old Adults. Biol Psychiatry. 199 Jun 1;45(11):1472-1480.

73. Paulionis L, Kane SL, Meckling KA. Vitamin Status and Cognitive Function in a Long-Term Care Population. BMC Geriatrics. 2005 Dec 13;5:16.

74, Masuda Y, Kokubu T, Yamasshita M, et al. EGG Phosphatidylcholine Combined With Vitamin B12 Improved Memory Impairment Following Lesioning of Nucleus Basalis in Rats. Life Sci. 1998;62(9):813-822

75. Hung MC, Shibasaki K, Yoshida R, et. Al. Learning Behavior and Cerebral Protein Kinase C, Anti-Oxidant Status, Lipid Composition in Senescence-Accelerated Mouse: Influence of a Phosphatidylcholine-Vitamin B12 Diet. Brit J Nutrition. 2001 Aug;86(2):163-171.

76. Thal LJ, Fuld PA, Masur DM, et. al. Oral Physostigmine and Lecithin Improve memory in Alzheimer Disease. Ann Neurol. 1983 May;13(5):491-496.

77. Zanelli SA, Solenski NJ, Rosenthhal RE, Fiskum G. Mechanisms of Ischemic Neuroprotection by Acetyl-L-Carnitine. In Neuroprotective Agents: Seventh International Conference. Slikker, W, Andrews RJ, Trembly B Eds. New York Acad Sci. 2005;1053:153-161. Anatural@ Co Q 10, Lipoic Acid and L-Carnitine

78. Virmani A, Gaetani F, Binienda Z. Effects of Metabolic Modifiers Such as Carnitines, Coenzyme Q 10 and PUFA=s Against Different Forms of Neurotoxic Insults: Metabolic Inhibitors MPTP, and Methamphetamine. In Neuroprotective Agents: Seventh International Conference. Slikker, W, Andrews RJ, Trembly B Eds. New York Acad Sci. 2005;1053:183-191.

79. LeBars PL, Kastalen J. Efficacy and Safety of a Ginko Biloba Extract. Publ Health Nutr. 200 Dec;3(4A):495-499.

80. MacDougall DS. Testosterone Replacement Therapy Beneficial for Men with Alzheimer=s Disease. Int Med New. 2006 Jan;20(1):33.

81. Selvin E, Coresh J, Golden SH, et. al. Glycemic Control and Coronary Heart Disease Risk in Persons With and Without Diabetes. The Atherosclerosis Risk in Communities Study. Arch Intern Med. 2005;165:1910-1916.

81. Quinones MJ, Hernandez-Pampaloni M, Schelbert H, et. al.Coronory Vasomotor Aabnormalities in Insulin-Resistant Individuals. Annal Int Med. 2004;140(9):700-708.

82. Ferreria I, Henry RMA, Twisk JWR, et. al. The Metabolic Syndrome, Cardiopulmonary Fitness, and Subcutaneous Trunk Fat as Independent Determinants of Arterial Stiffness. Arch Int Med. 2005;165:875-882.

84. Edwards DA, et al. EDTA Chelation Therapy in Myocardial Stunning and Hibernation. J Advancement Med 1997;10:233-257

85. Edwards DA, et al. Hibernation and Stunning of Peripheral Arterial Myocytes: Clinical Reversal by EDTA Chelation Therapy (poster presentation). In Vascular Endothelium Pharmacologic and Genetic Manipulations [eds: Catravas JD, Callow AD and Ryan US]. NATO ASI Series, Plenum Press; 1998:255-257.

86. Despres JP, Golay A, Sjostrom L. Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipemia. N Engl J Med. 2005;353:2121-2134.